2024
High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine
Ottesen T, Wickersham J, Lawrence J, Antoniak S, Zezuilin O, Polonsky M, Antonyak S, Rozanova J, Dvoriak S, Pykalo I, Filippovych M, Altice F. High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine. PLOS ONE 2024, 19: e0305086. PMID: 39028735, PMCID: PMC11259278, DOI: 10.1371/journal.pone.0305086.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy prescriptionAntiretroviral therapyCD4 countSubstance use disordersIncreased levels of stigmaNational sampleLevel of stigmaIndependent of risk groupSuboptimal antiretroviral therapyInitiate antiretroviral therapyPopulation of peopleHIV expertsHIV incidenceHIV physiciansHIV treatmentKey populationsTransgender womenAntiretroviral treatmentFeeling thermometerDrinking alcoholSex workersPhysiciansSex partnersPWHRisk groups
2023
Barriers and Facilitators to Pre-Exposure Prophylaxis by Men Who Have Sex with Men and Community Stakeholders in Malaysia
Rosen A, Wickersham J, Altice F, Khati A, Azwa I, Tee V, Jeri-Wahrhaftig A, Luces J, Ni Z, Kamarulzaman A, Saifi R, Shrestha R. Barriers and Facilitators to Pre-Exposure Prophylaxis by Men Who Have Sex with Men and Community Stakeholders in Malaysia. International Journal Of Environmental Research And Public Health 2023, 20: 5669. PMID: 37174187, PMCID: PMC10177799, DOI: 10.3390/ijerph20095669.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsHIV InfectionsHomosexuality, MaleHumansMalaysiaMalePre-Exposure ProphylaxisSexual and Gender MinoritiesConceptsPre-exposure prophylaxisPrEP providersNominal group techniqueMalaysian MSMEvidence-based HIV prevention strategiesPatient-centered decision aidAwareness of PrEPHIV prevention strategiesPotential new strategyPrEP deliveryPrEP carePrEP initiationPrEP servicesPrEP uptakeDecision aidPrevention strategiesUnderstanding of barriersComplex clinical protocolsClinical protocolsMSMQualitative focus groupsCommunity stakeholdersPrEPProphylaxisMen
2022
Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder
Eger WH, Altice FL, Lee J, Vlahov D, Khati A, Osborne S, Wickersham JA, Bohonnon T, Powell L, Shrestha R. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder. Harm Reduction Journal 2022, 19: 120. PMID: 36307817, PMCID: PMC9616614, DOI: 10.1186/s12954-022-00703-8.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsHIV InfectionsHumansOpioid-Related DisordersPre-Exposure ProphylaxisSubstance Abuse, IntravenousConceptsSame-day prescriptionPre-exposure prophylaxisOpioid use disorderHIV transmissionUse disordersClinical stakeholdersAvailability of providersSystems of careHealth care systemCoordinated careNew practice modelClinical careMedicationsPharmacy deliveryMOUDNominal group techniqueLocal prescribersPWIDSexual riskPrEPCare systemHealth benefitsCareMultiple visitsProphylaxisA PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks
Meyer JP, Price CR, Ye Y, Qin Y, Tracey D, Demidont AC, Melbourne K, Altice FL. A PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks. AIDS And Behavior 2022, 26: 3807-3817. PMID: 35672552, DOI: 10.1007/s10461-022-03709-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCommunity-Institutional RelationsFemaleHIV InfectionsHumansPre-Exposure ProphylaxisTelemedicineConceptsTDF/FTCPrEP care continuumPre-exposure prophylaxisPrimary care providersPrEP demonstration projectRisk network membersNon-Hispanic whitesCisgender womenOutreach modelRespondent-driven samplingPrEP awarenessCommunity outreach modelEnrolled participantsMean ageClinical criteriaIndex participantsCare continuumHIV preventionSocial comorbiditiesCare providersKey populationsPrEPSubstance useMedical insuranceWomenPreferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study
Gutierrez JI, Vlahov D, Dubov A, Altice FL. Preferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study. Journal Of Urban Health 2022, 99: 277-292. PMID: 35318573, PMCID: PMC9033922, DOI: 10.1007/s11524-022-00615-9.Peer-Reviewed Original Research
2021
Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust
Zhou X, Altice FL, Chandra D, Didomizio E, Copenhaver MM, Shrestha R. Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. AIDS And Behavior 2021, 25: 3743-3753. PMID: 33751313, DOI: 10.1007/s10461-021-03227-7.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisPrEP useProvider trustPatient-level factorsOpioid-dependent patientsLogistic regression analysisNon-homeless participantsHomeless participantsRace/ethnicityEligibility criteriaCross-sectional dataPrEPProphylaxisMethadoneRegression analysisDrugsExploratory findingsParticipantsPotential moderatorsPWIDPatientsSignificant moderator
2020
Integrating HIV pre‐exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study
Bórquez A, Rich K, Farrell M, Degenhardt L, McKetin R, Tran LT, Cepeda J, Silva‐Santisteban A, Konda K, Cáceres CF, Kelly S, Altice FL, Martin NK. Integrating HIV pre‐exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. Journal Of The International AIDS Society 2020, 23: e25495. PMID: 32562365, PMCID: PMC7305413, DOI: 10.1002/jia2.25495.Peer-Reviewed Original ResearchConceptsMSM/transgender womenHIV pre-exposure prophylaxisPre-exposure prophylaxisNew HIV infectionsHIV infectionTransgender womenStimulant useCVD mortalityCVD deathHealth harmsIntegrated substance useMore HIV infectionsHigh HIV incidenceCardiovascular disease mortalityRandom allocationUnprotected anal sexRisk of suicideHIV incidenceHIV transmissionDisease mortalityHIV riskGlobal systematic reviewAnal sexReduction interventionsSystematic reviewAwareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disordersSafety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy
Gonzales P, Grieco A, White E, Ding R, Ignacio RB, Pinto-Santini D, Lama JR, Altice FL, Duerr A. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLOS ONE 2020, 15: e0228433. PMID: 32134956, PMCID: PMC7058313, DOI: 10.1371/journal.pone.0228433.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyClinical adverse eventsAdverse eventsTransgender womenUse disordersDouble-blind randomized placebo-controlled trialMSM/transgender womenRandomized placebo-controlled trialART-naïve participantsPossibility of hepatotoxicityPlacebo-controlled trialSerious adverse eventsHIV-positive menMedication-assisted therapyProportion of subjectsAdverse event dataMultiple new medicationsOral naltrexoneStudy medicationTransaminase elevationPlacebo armNTX treatmentTreatment armsNew medications
2019
Dual motivational model of pre-exposure prophylaxis use intention: model testing among men who have sex men in Ukraine
Ranjit YS, Dubov A, Polonsky M, Fraenkel L, Rich KM, Ogunbajo A, Altice FL. Dual motivational model of pre-exposure prophylaxis use intention: model testing among men who have sex men in Ukraine. AIDS Care 2019, 32: 261-266. PMID: 31288547, PMCID: PMC6937373, DOI: 10.1080/09540121.2019.1640845.Peer-Reviewed Original ResearchRationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study
Shrestha R, Altice FL, Sibilio B, Ssenyonjo J, Copenhaver MM. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials 2019, 82: 77-84. PMID: 31229618, PMCID: PMC6639056, DOI: 10.1016/j.cct.2019.06.012.Peer-Reviewed Original ResearchConceptsBio-behavioral interventionHIV risk reductionOpioid-dependent peopleMethadone maintenance programPrEP adherenceHIV transmission risk reductionFirst prospective trialPre-exposure prophylaxisHIV prevention strategiesOngoing drug useRisk reductionBehavioral skills modelProspective trialSecondary outcomesPrimary outcomeRisk reduction outcomesHIV riskWeek 20Prevention strategiesUnmet needDrug useHybrid type IBio-behavioral approachProcess evaluationAdherenceHIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy
LaMonaca K, Dumchev K, Dvoriak S, Azbel L, Morozova O, Altice FL. HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy. Current Psychiatry Reports 2019, 21: 47. PMID: 31161306, PMCID: PMC6685549, DOI: 10.1007/s11920-019-1038-8.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programDrug injectionAntiretroviral therapyHIV epidemicEvidence-based HIV prevention strategiesNew HIV casesHIV prevention strategiesHarm reduction programsAgonist therapyHIV incidenceHIV casesRecent FindingsThoughPrevention strategiesSexual partnersHIVInjectionTherapyReduction programsEpidemicPunitive drug lawsService programsMortalityCliniciansIncidenceHIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients
Shrestha R, Altice FL, Copenhaver MM. HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 166-173. PMID: 30383588, PMCID: PMC6331231, DOI: 10.1097/qai.0000000000001891.Peer-Reviewed Original ResearchConceptsOptimal ART adherenceAntiretroviral therapyMethadone-maintained patientsMethadone maintenance treatmentART adherenceMaintenance treatmentHIV treatment outcomesHIV-positive patientsOpioid agonist therapyMultivariable logistic regressionHIV risk behaviorsExplanatory pathwaysAgonist therapySuboptimal adherenceMedication adherenceHIV treatmentTreatment outcomesHIV stigmaPatientsLogistic regressionHIVPrevention initiativesTherapyAdherenceSignificant correlates
2018
Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru
Rich KM, Wickersham JA, Huamaní J, Kiani SN, Cabello R, Elish P, Arce J, Pizzicato LN, Soria J, Sanchez J, Altice FL. Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru. LGBT Health 2018, 5: 477-483. PMID: 30874476, PMCID: PMC6306649, DOI: 10.1089/lgbt.2017.0186.Peer-Reviewed Original ResearchConceptsHIV-positive transgender womenViral suppressionTransgender womenUse disordersViral suppression ratesHIV viral suppressionMultivariable logistic regressionAdverse health outcomesSubstance use disordersAlcohol use disorderSevere drug useUse of drugsHIV statusSubstance disordersHigh burdenHigh prevalenceCondomless sexPsychiatric disordersAnal sexFactors AssociatedHealth outcomesDrug useHIV researchLogistic regressionLast partnerOpioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareRetention in HIV care during the 3 years following release from incarceration: A cohort study
Loeliger KB, Meyer JP, Desai MM, Ciarleglio MM, Gallagher C, Altice FL. Retention in HIV care during the 3 years following release from incarceration: A cohort study. PLOS Medicine 2018, 15: e1002667. PMID: 30300351, PMCID: PMC6177126, DOI: 10.1371/journal.pmed.1002667.Peer-Reviewed Original ResearchConceptsViral suppressionInjection drug useHIV careCohort studyTreatment outcomesDrug useNational HIV prevention strategyMultivariable logistic regression modelCase management visitsProportion of followRetrospective cohort studyEarly linkageHIV prevention strategiesLongitudinal treatment outcomesHealth insuranceBetter treatment outcomesSubstance use disordersCase management servicesLogistic regression modelsAntiretroviral therapyCohort participantsManagement visitsCriminal justice populationsLarge cohortPsychiatric disordersPre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis
Ranjit YS, Dubov A, Polonsky M, Fraenkel L, Ogunbajo A, Mayer K, Altice FL. Pre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis. AIDS And Behavior 2018, 23: 534-543. PMID: 29980993, DOI: 10.1007/s10461-018-2214-2.Peer-Reviewed Original Research
2017
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study
Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. The Lancet HIV 2017, 5: e96-e106. PMID: 29191440, PMCID: PMC5807129, DOI: 10.1016/s2352-3018(17)30209-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesHIV careViral suppressionTreatment outcomesPoor HIV treatment outcomesMore medical comorbiditiesPost-release linkagePredictors of linkageRetrospective cohort studyDetectable viral loadCase management servicesCase management dataTransitional case managementHealth care goalsAntiretroviral therapyMedical comorbiditiesCohort studyRetrospective cohortDays of releaseViral loadPharmacy databasePsychiatric comorbidityUS National InstitutesCase management needsHispanic ethnicity
2016
Co-calibration of two self-reported measures of adherence to antiretroviral therapy
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2016, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.Peer-Reviewed Original ResearchConceptsVisual analog scaleAntiretroviral therapyAdherence measuresAIDS Clinical Trials Group questionnaireHigh-risk vulnerable populationsVulnerable populationsCare cohortAnalog scaleVAS scaleHIV StudyAdherence dataClinical successConsortium studyGroup questionnaireTherapyDosesSelf-report measuresAdherenceCommunity-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets
Nachega JB, Adetokunboh O, Uthman OA, Knowlton AW, Altice FL, Schechter M, Galárraga O, Geng E, Peltzer K, Chang LW, Van Cutsem G, Jaffar SS, Ford N, Mellins CA, Remien RH, Mills EJ. Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Current HIV/AIDS Reports 2016, 13: 241-255. PMID: 27475643, PMCID: PMC5357578, DOI: 10.1007/s11904-016-0325-9.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCommunity Health CentersCross-Sectional StudiesDeveloping CountriesHealth EducationHealth Services AccessibilityHIV InfectionsHumansMedication AdherenceObservational Studies as TopicPatient DropoutsRandomized Controlled Trials as TopicSustained Virologic ResponseUnited NationsConceptsHealth facility-based interventionsFacility-based interventionsAntiretroviral therapy adherenceCommunity-based interventionsVirologic suppressionCohort studyMiddle-income countriesClinical outcomesTherapy adherenceRelative riskComparable outcomesCommunity-based ART delivery modelTreatment engagementART delivery modelsFacility-based modelsComparative cohort studyRelevant clinical outcomesRandom-effects modelLeast comparable outcomesStable HIVCause mortalityHIV careART adherenceUNAIDS 90ART delivery